Archive for Opinions

2006 and all that (part 2)

Reasons to be cheerful..

Too much to read….
Here’s a plot similar to the ones I produced in the very first post on this blog. It clearly shows the increase in publications in the past year relating to four of the most well-known genes in the context of either schizophrenia or bipolar disorder.
graph06

I think this reveals more about the high activity of the field than the candidacy of any one particular gene.

Supporters in high places…

From Google:

“James D. Watson, Nobel Laureate and Chancellor of Cold Spring Harbor Laboratory, describes the years leading up to his 1953 discovery of
Click here for the speech (starts about 7 minutes into running time).

A new textbook for the new year

dummies

Comments

2006 and all that (part 1)

Here is a roughly collated list of the gene candidates for schizophrenia and bipolar disorder studied by labs across the World in 2006 (definitely not exhaustive: mostly taken from association study papers where the gene in question might have shown association or not).

5HTT
ADRA2A
AHI1
ALG9
ALK
APOD
APOE4
ARNTL
ASCT1
ASPM
ATRAR4R
BDNF
BRD1
C6ORF217
CALRETICULIN
CAPON
CC16
CD14
CHROMOGRANINA
CHI3L1
CHRFAM7A
CHRNA7
CHROMOGRANIN3
CLOCK
CNP
CNR1
CNTF
COMPLEXIN1
COMPLEXIN2
COMT
CYP1A2
DARPP-32
DAT
DGCR14
DGCR2
dihydropyrimidinase-related protein 2
DISC1
DPYSL2
DRD1
DRD2
DRD3
DRD4
DTNBP1
DUSP6
EPSIN4
ERBB4
FAT
FEZ1
FGF2
FGFR1
FKBP5
FOXP2
FZD3
G72/G30
GABRB2
GAD1
GAD67
GLYT2
GNAS1
GNPAT
GPR24
GPR50
GPR78
GRIA1
GRIK3
GRIK4
GRIK5
GRIN1
GRIN2A
GRIN2B
GRK3
GRM3
GSK3B
HTR2A
IL10
IL3
INPP1
KCNN3
KIF1
KPNA3
KPNB3
kynurenine 3-monooxygenase
MAP6
MIF
MNSOD
MPZL1/PZR
MTHFR1
NAPG
NCAM1
NDUFV2
NET
NEUROGENIN1
NEUROGRANIN
NEUROPLASTIN
NLGN4
NOGO
NOS3
NOTCH4
NPAS3
NRG1
NUMBL
OLIG2
P2RX7
PCDH11Y
PCM1
PDLIM5
PER3
PICK1
PIP5K2A
PLA2G4A
PLXNB3
PRODH
PSD95
QKI
RGS4
RLN
SCYA2
SERINE RACEMASE
SIAT8B
SLC6A4
SMARCA2
SOX10
SYNAPSIN-III
synaptogyrin 1
synaptotagmin XI
TAAR6
TCP1
TNFA
TNFB
TNXB
TPH1
TRPM2
UCP
VMAT1
XBP1
ZDHHC8

On the face of it we should be congratulating ourselves on the rate of progress in the field - so many candidates to hold up to funders/press/public as important contributors to disease.

But is this the real picture? Could this breadth of study be highlighting the rather clueless and arbitrary manner in which genes are selected for study….and the failure of the field to commit to systematic replication of positive results. Let’s face it, how many of the new genes discovered last year are going to be the subject of follow-on studies? Very few, I’m sure…which renders the initial findings as non-results. That’s a little hard perhaps but imagine where we could have been if the field had carried out the equivalent of ‘SETI at home’….distributed genotyping of a limited set of genes. We could be here digesting our mince pies in the warm afterglow of some definitive answers.

The real New Year downer is the total lack of identified mutations in these genes. P2RX7 is the only gene with a decent set of follow-up statistical work on its population-level mutation….the other 141 genes still have no nailed-down, bona-fide point mutations showing association with illness. This is astonishing and verging on the shameful, especially when it is considered that some of the BIG genes have extensive and expensive functional/structural and behavioural/cognitive work carried out on them without the genetics being anywhere near a cast-iron certainty. Like house prices, this situation is untenable in the long run so everyone should keep their fingers crossed that their favourite gene doesn’t become ‘negative equity’ in 2007.

My New Year hope is that labs will take the plunge into resequencing candidate genes fully in carriers of associated haplotypes. If we have the conviction to publish the association studies then we have to have the conviction that mutations are underlying our haplotypes. In my mind, resequencing projects should be the natural successors to the BIG-funded whole-genome association studies.

Let’s hope that 2007 doesn’t end with a turkey too.

Comments

Horses for courses, not flogging

The challenge
I’m open to comments from those that think the following isn’t correct…..
So you have a lab and DNA samples donated with consent from individuals diagnosed with a psychiatric illness and a matched group without illness. How would you go about telling us something about the genetics of psychiatric illness? You’d think the strategy would be already well worked out…a simple recipe of experimentation and analysis which would give you the answer.

To borrow from W. Somerset Maugham:

There are three rules for cloning complex disease genes. Unfortunately, no one knows what they are.

The problem is circular…until we have a few of these genes in the bag we won’t know the best way to get them. Here, ‘in the bag’ means proper mutations, not inferred involvement.

In this post, I will tell you what I think you should NOT do (the horse-flogging bit) and some suggestions on what you should do (the horses for courses bit) given the nature of your starting materials.

Don’t try this at home (or in the lab)

Genome-wide linkage studies….or more precisely, multiple family genome-wide linkage studies. In essence, linkage looks for regions of chromosomes which seem to always be found in family members who have the particular condition being studied. The implication is that these regions contain the faulty gene. The snag comes when you go beyond looking at a single family and instead ask what regions of chromosomes are linked with the disease in all families, or most…or even a detectable proportion. It hasn’t and doesn’t work when you go beyond the single family. An Aesop fable may help you see why (although it should be blindingly obvious).

The King of Clonia loved his orchard and the bountiful fruit it produced each year. It covered a sizeable area of his palace grounds and consisted of a multitude of fruiting tree species collected and nurtured from all over his Kingdom. One day, in a fit of ill-advised enthusiasm, he issued an edict to his court alchemists.

“Identify the purest essence of each individual fruit so that I might bottle them all as a gift to the Queen”.

The Alchemists debated over this task and finally came up with this solution. They would collect one example of each fruit, place it in a single barrel and grind them all up. Then they would extract, filter and fractionate the essences in one glorious process.

“That’s crazy”, cried one dissenting Alchemist, “you are just making the problem more difficult…how will you tell orange essence from apple or from plum?”.

“Fool!”, they replied witheringly, “we have the power to detect all the essences simultaneously…the court arithmetician has decreed it so”.

They failed of course, but as is the wont of those convinced by statistical models, they decided that scaling up was the answer.

“More fruit for the barrel!!” went out the command. “Still more fruit!!”, as they failed again.

The moral of the story is made apparent when the ‘fool’ took the fruit of a single, large tree and extracted the essence as required. Rather than praise his efforts, the other Alchemists accused him of plucking low-hanging fruit and producing an essence that was not relevant to the orchard as a whole.

“Your essence looks nothing like ours…and doesn’t even look like that you got from looking at another big tree”, they said.

“Exactly! That’s the point! Isn’t it good!”, he exclaimed excitedly.

“Actually, we think that means you have made a mistake. Or the problem is intractable. Or that fruit beetles must be invoked as the guardians of the essence and must be factored into future extractions”, the Alchemists said without a hint of irony.

The King placed all of them in a specially commissioned barrel and left them to stew in their own juices.
The end.

Are families bad? A graphical answer

No! They are good. But you have to know how to use them correctly to get any meaningful genetic information from them. It all comes down to my favourite phrase, ‘genetic architecture’. How many mutations are there for a disease in the population, how common are they in the population, how strong is each one’s effect and do they run in families or are they ’sporadic’? The graphs below are my attempt to illustrate a genetic model that tries to explain that all of these questions are, in fact, just flip-sides of the same coin….and what is more, this genetic model can tell us what analysis techniques we should use when given a particular DNA sample set.
fig1

This first graph shows that the amount of each mutation in the population (its frequency) is directly related to how ’strong’ its effect is (names like Odds Ratios are just genetics terms for measuring mutation effect strength). This is the critical concept which helps explain the rest. Common mutations have weak effects and rare mutations often have strong effects….and every combination in between - as shown by the wide yellow band.
fig2

The pretty obvious fact (you would think) is that if a mutation has a strong effect then it will be apparent in most individuals it is passed on to. Hence, it will be recorded as evidence of a family history. In terms of ascertainment bias (shiny things grab our attention), it will highlight a family, catching the eye of a physician collecting DNA samples for a gene-hunting exercise. Weak effect mutations will probably have to work together to push an individual down the route of illness - but that’s OK as they are generally common and likely to be inherited together by chance in unlucky people (note the use of inherited here…it is not a process any different from the nominally familial individuals). But these individuals won’t be part of the families - they will appear as ’sporadic’ cases, caused by the random convergence of population risk factors.

Methods are horses and DNA sets are courses
fig3

So this figure is the crunch. We have this model but how do we apply it? Well each experimental technique/method of data analysis has its strengths and weaknesses. I think that researchers should be very, very careful when looking at the DNA sample set in front of them and deciding what they want to do. If it is a familial heavy set (left-hand side of the graph) then you would want to do single large family genome-wide linkage studies, the related technique of following the co-segregation of candidate gene alleles and illness through a family or, finally, deep resequencing. This final technique is not really applied much as it requires the selection of a candidate gene and then sequencing this gene in many DNA samples from individuals with a family history. The idea is that you may be lucky and hit a rare, strong effect (’highly penetrant’ in genetic-speak) mutation.

If, on the other hand (right of the graph), you have a predominantly sporadic DNA sample set than this opens up the possibility of case-control association studies. This technique compares the frequency of candidate gene alleles (’flavours’ of the same gene) between people with illness and unaffected people. If a difference is seen then that gene allele indicates the nearby presence of a mutation. This approach requires the alleles to be reasonably common in the population otherwise they will not be detectable. Hence, case-control association studies and familial (rare allele) samples shouldn’t be combined…..if you want anything out the other end. This is entirely analagous to the multiple family genome-wide linkage problem….here the issue is the number of different fruit types combined in the barrel - you won’t taste the bad apple in your fruit smoothie.
We are entering the age of the whole-genome case-control association study where big-science does away with subjective choice of candidate genes and just screens everything. While the rather poor coverage of each gene (and its constituent LD blocks) might sometimes work against the aims of the experiment - a story for another time, perhaps - let’s hope that nobody applies the wrong DNA sample set and then looks puzzled when results are lacking……..

Comments

Sex and protection: breaking the taboos

A gene for…

Barely a week goes by without a press release describing the identification of ‘a gene for X disorder’. But what does that mean exactly? Naturally, it doesn’t mean that the purpose of that gene is to cause the disorder - rather, damage to that gene (a mutation) directly causes, or increases the risk of, disorder X. The normal function of that gene, probably making a protein which has a role in some process in the cell, has been changed in a harmful way. Maybe the ‘encoded ‘ protein is not made, or its activity is changed.

Cases and controls

Schizophrenia and bipolar disorder are complex genetic disorders which means that each individual gene mutation is likely only to contribute to a small fraction of illness in the population (even if it can be a major contributory factor for particular affected individuals). That is why ‘case-control association studies’ are employed by researchers wishing to assess how important their particular gene of interest is in the general scheme of things. Basically, they use natural gene variants (sequence differences) that exist in the population and ask whether they are more common in individuals with the disorder (cases) compared to the well population (controls). If the variant is more common then either it, (or more likely) a mutation nearby in the gene, is responsible for predisposing some people towards developing the illness (the variant, and the gene in general, is said to be ‘associated’ with the illness).

Strange associations

Even though the title of this post is a little misleading, there have been some unexpected and provocative findings from association studies that have been treated with great suspicion (generally by those who review the data presented in scientific papers). In brief, some genes seem to contribute to illness in one ‘sex‘ only and other genes seem to offer ‘protection‘ against illness rather than contributing to it. Because the strength of these studies critically depends on the number or cases and controls used (the more, the better the study) and the mathematical analyses used, it is easy for those suspicious people mentioned above to dismiss these observations as mere ‘lies, damned lies and statistics’ - researchers trying to wring something of interest from their favourite gene.
If you don’t look, you won’t find…
Perhaps these findings are only a surprise because the older, and more widely used, method of gene hunting - ‘linkage analysis’ - is not well-equipped to find such associations. Firstly, to find a protective effect for a gene would require a linkage-using researcher to look for ‘well’ families - the opposite of normal - and ask why they were normal. Not a particularly precise approach - and one not likely to find financial support for investigation. [Having said that....] Linkage studies can also examine if an illness is passed down a maternal or paternal line (indicating processes such as imprinting, mitochondrial disease or sex-linkage…topics that I can’t do justice to here) but which gender is affected is not often monitored.

So the advent of widespread asociation studies has revealed these two peculiarities, but is there any biology to explain them? Let’s look at protective effects first.

Newtonian genetics

One explanation of the observation of protection is a simple mathematical counterpart of ‘an action causing an equal and opposite reaction’. Below, I’ve pasted in a real-world example of some data from a gene, NPAS3, we are working on (the data is being presented initially at the World Congress of Psychiatric Genetics in Sardinia this weekend).

Slide1

One part of the gene has 6 principal variants (‘haplotypes’: 111, 121….etc.). The four columns for each variant represent how common each one is in healthy control individuals (CONT), individuals with schizophrenia (SCZ), individuals with bipolar disorder (BPD) and a combined group made up of both conditions (COMB). What you can see is that there is a big shift for the ‘212’, and to a lesser extent, ‘211’, variants. 212 appears to represent a ‘susceptibility’ variant (more common in cases) whereas 211 seems to be a ‘protective’ variant (lower in cases). But is it really? A more plausible explanation is that the 211 decrease is just a passive response to the 212 increase – something has to ‘give’ to compensate for more people being in the 212 group. If indeed this is the case, then the other variants would also show a similar (if proportional) drop. 122 fits this model nicely but the others are not so clear - so you can see how this is not always the easiest trend to spot. Incidentally, the SCZ and COMB groups for 212 show the most statistically significant p-values for this data set (an indication, perhaps, that they are the driving force in this shifting picture).

Real protection

A clearer picture of protection comes from the study of the genes GRIK4 and DISC1…… In the former case (link to review in the Schizophrenia Research Forum) there is a schizophrenia susceptibility region in the centre of the gene and a clear bipolar disorder protective variant (haplotype) at the end of the gene which is present in around 16% of individuals with bipolar disorder and about 23% of control individuals.

We are all schizophrenic…….

Let me propose a strange and unlikely situation where the forces driving the evolution of the human brain have led to schizophrenia (or bipolar disorder) becoming more prevalent….possibly even the default state. In a contemporaneous evolutionary arms race, gene variants would have appeared and been selected for their protective effect against schizophrenia. In this way a large set of protective variants might exist at relatively high frequencies in the population such that 99% of people would not develop the disorder.

This is an exaggeration to make the point that it would be theoretically possible to construct a genetic model of schizophrenia using only protective factors. However, despite its wackiness, there are a couple of concepts in complex genetic disorder-speak that seem to cry out for an acknowledged role for protective variants. First, there is ‘reduced penetrance’, which refers to the phenomenon where mutation carriers don’t always develop the full-blown disease. Something is compensating for the mutation. This ‘something’ is often described as ‘genetic background’ - a rather nebulous term meaning ‘a whole load of genetic (and maybe environmental) influences we cannot hope to quantify or understand’. Surely, it would be better to bite the bullet and admit that some of the protective variants we are observing could be active components of this background? Second, and closely related, is the concept of disease ‘threshold’ – susceptibility and, by implication, protective factors, are competing in a genetic tug-of-war. The net result is that the host human ends up on one side or other of the disease threshold.

The next phase of industrial scale genetic research into psychiatric disorders will involve the use of ‘whole genome associations’ – testing each gene simultaneously for its role in illness. I predict that people are going to be surprised at just how many gene variants are protective. I also predict that these variants might give us more of an idea of the biological strategies that could be adopted in the rational design of new therapies – essentially, we would be following Mother Nature’s lead.

Gender issues

If you find the idea of protective factors is rather outlandish, then the existence of gender-specific associations is going to be even harder to accept. The fact is that some gene variants only seem to alter the risk of illness when you look at just one sex in isolation. DISC1’s effect on both bipolar disorder and schizophrenia (Thomson et al 2005) and GPR50 on bipolar disorder (Thomson et al 2005) are both clear examples of this phenomenon. I think that some of the prejudice against the existence of sex-specific associations comes from the misapprehension that this doesn’t fit with the commonly quoted fact that schizophrenia and bipolar disorder affect both sexes equally. I would argue that, just as there are multiple susceptibility and protective variants, there are likely to be multiple male-specific and female-specific variants – the biases must average themselves out in the end. Having said that, my concern at present is that most sex-specific associations seem to be female in type.

What about biological mechanisms? There is an established and growing set of non-psychiatric genes that also possess sex-dependent risk variants (Weiss et al 2006). For example, a gain-of-function mutation with a sex-specific (and protective) effect against Parkinson Disease (Glatt et al 2006) and a sex-dependent risk polymorphism for non-familial Hirschsprung disease (Emison et al 2005) have both been recently described and go some way towards a functional explanation for such phenomena. Schizophrenia usually has its onset post-pubertally in teenage and early adult life in both sexes. As both these sex-specific examples result from regulatory polymorphisms, hormonal influences on transcriptional control can be postulated as an underlying mechanism – as documented for the cAMP response element binding (CREB) protein (Auger 2003, Abraham et al 2005, Zubenko et al 2003). In other words, a gene variant would exist in both sexes as per normal genetic rules, but it only has a biological consequence in one sex because of an altered interaction with some sex-hormone-linked process. Hence, a plausible strategy for future research would be a search for neuroendocrine-modulated intronic regulatory element polymorphisms in the DNA of carriers of sex-specific variants.

In summary, we have had a glimpse of some intriguing variations to the normal risk gene action for psychiatric illness. It will be interesting to see how these phenomena develop over the next few years.

Comments

Semantics = Some antics

While all would agree that the belief of the layman (read media) that ’schizophrenia’ refers to a split mind or split personality is highly irritating, I think the views expressed by these people are unhelpful.

This action group known as CASL aim to do away with the term schizophrenia but do not specify what it should be replaced with.

As a word, schizophrenia doesn’t seem to have that vaguely pejoritive feel that former medical terms for learning disability/mental retardation did. I can understand those people with the disorder not wishing to be known as ’schizophrenic’ but rather ‘diagnosed with schizophrenia’…..this latter phrasing maintains their human individuality.

My hope is that the fields of genetics and molecular neurobiology will be able to provide a more fact-based subdivision of psychiatric illnesses into particular categories. Until that time, I think it is premature to be thinking about new names. That would only act to distract from the real issues of treatment and scientific investigation.

Comments

Quis custodiet ipsos custodes?

Here are a couple of links spotted on Metafilter that raise the issues surrounding how, and by whom, science papers are judged suitable for publication in journals. The first link discusses possible changes and the second highlights the strategy taken by the journal Nature.

Perhaps rather an esoteric subject, but one that occupies the minds of researchers a great deal.
Would a new reviewing process - perhaps based on ‘live’ editing/reviewing - help fix some of the problems associated with anonymous peer review?

  1. It may help a small field like psychiatric genetics where papers are likely to be reviewed by a competitor. Live reviewing might dilute, or require justification of, criticism based on axe grinding.
  2. Who is going to spend time on live review of small papers in the lower journals? I can’t see sparkling, erudite discussions on a the analysis of an over-employed polymorphism in a hackneyed candidate gene and its proposed effect on a minor pseudo-psychiatric phenotype.
  3. When will a live reviewed/edited paper ever be deemed complete? Will it be ‘re-opened’ for butchery should opinions change over time?
  4. Just like big editorial personalities can determine the content of a journal, will vociferous hawks push publications (and research) in unhelpful directions?

Comments

Theory revisited: Schizophrenia - the cost of being human

You may have seen the various press snippets (link 1, 2, 3, 4) surrounding the advanced online publication of a paper in the journal Nature this week (also comment in John Hawks’ Blog). This work is part of a field where bioinformaticians (those who study the large sets of data generated by projects such as the Human Genome Project and the HapMap Project) study the evolutionary footprints that are to be found in the DNA sequence of our chromosomes.

Since the Human Genome Project was completed five years ago, it has been joined by genome projects from a wide variety of inhabitants of the evolutionary tree so that it is possible to dissect the genetic differences between them. In the most part, this has been used to identify similarities between species. These ‘conserved’ regions have arisen because they have been subject to strong selective pressure not to accrue random mutations. Conserved regions usually indicate the presence of genes (which have to be kept intact in order to make functional protein) or regulatory regions (which control the use of particular genes). You can think of these conserved regions as being responsible for the core properties of a protein, and on a larger scale, responsible for the general features of an organism - head, limbs, organs, metabolism, muscle etc. It also stands to reason that mutations in these conserved regions are likely to have the most serious consequences……that of causing genetic disorders.

However, some researchers have looked at the flipside of this coin - hunting out the regions of the genome which show the greatest differences between species. These, it is hypothesized, represent the sites where natural selection and speciation events have occurred - they are responsible for what makes us different from our evolutionary ancestors.

This Nature paper details the application of this latter approach: the assumption that genes showing fast evolution between the homininae lineage (human, chimpanzee, gorilla and orang-utan) and hominina lineage (humans and their ancestors since the split with chimpanzees circa 6 million years ago) are responsible for our defining and distinguishing evolutionary features, in particular, increased brain size/cognitive power.

So, in brief, the reasoning goes like this: fast-evolved human genes > used in brain > they made us what we are today.

It’s not the first time that such an approach has been tried. Indeed, genes such as ASPM and Microcephalin have shown fast evolution and appear to play a role in brain development (lots of nice reviews here: link 1, link 2, link 3, link 4). There are even genes which are entirely specific to humans - for example the SIGLEC11 gene is expressed in brain microglial cells.

The first author of the paper, Katherine Pollard, carried out a systematic screen of the human genome, comparing it with chimp, in order to identify what she calls ‘Human Accelerated Regions’ (HARs) - the fast-evolved regions. The most significant finding was called HAR1 and shows 66 times more sequence changes than would be expected of an average stretch of DNA. The HAR1 region seems to be correlated with two overlapping genes, HAR1F and HAR1R. The genes themselves are odd in that they don’t make proteins - their function must be carried out in their mRNA form. Most RNA genes are regulatory in that they control the actions of other genes, but no such role has yet been shown for HAR1F/R. Again, the authors show that this humanised gene acts in the brain, and more specifically, the developing foetal brain. It is found in the precursor cells that will go on to produce the cerebral cortex - the higher functioning, business end of the brain.

How does schizophrenia fit into this story? A related hypothesis follows directly on from the ‘fast-evolved human gene’ argument. This states that schizophrenia is a uniquely human disease caused by dysfunction of uniquely human cognitive faculties and is, therefore, likely to have genetic causation in those brain genes that have driven human speciation. In other words, genes like the HARs are possible candidates for schizophrenia genes. Here are three papers that originally stated this idea.

Brune, M. (2004) Schizophrenia-an evolutionary enigma? Neurosci Biobehav Rev 28 (1), 41-53

Randall, P.L. (1998) Schizophrenia as a consequence of brain evolution. Schizophr Res 30 (2), 143-148

Crow, T.J. (1995) A theory of the evolutionary origins of psychosis. Eur Neuropsychopharmacol 5 Suppl, 59-63

It has to be said that this idea has been in the wilderness for a while, overtaken by more pharmacological thoughts on the genes involved in schizophrenia. Does it deserve another shot at glory? It’s hard to say just yet, but there are a few intriguing clues:-

  1. HAR1F/R is found in the same cortex precursor cells as Reelin, itself a reasonably well-established schizophrenia candidate gene.
  2. Another brain capacity gene, like ASPM and Microcephalin, is Nde1 (’Nude 1‘) which is a direct interactor with the DISC1 schizophrenia candidate gene.
  3. A previous paper on fast-evolving brain genes identified GRIK4 (a glutamate responsive neurotransmitter receptor in the brain). We have just described its involvement in the genetics of schizophrenia and bipolar disorder.
  4. Similarly, the NPAS3 gene was identified as ‘HAR21′ (also incorrectly labeled HAR30 in table S8) by Pollard et al. We have shown that this gene is involved in schizophrenia too - and described a region of the gene/protein that is human-specific (although this is not the same region flagged up in HAR21).

Circumstantial at best maybe, but certainly the basis for future study.

What an chillingly emotive idea, though. The genetic forces that boosted our cognitive faculties in Africa’s Rift Valley may contribute to the debilitating characteristics of psychiatric illness.

Comments

Home genetic test for schizophrenia?

Peer-reviewed papers in respectable journals are to press releases what spring water is to cheap sparkling wine. Trawling the interweb, I came across this. I’m afraid you have to register to view the full article but it basically distills down to an early fanfare for the upcoming production of a home test for schizophrenia. The article describes very little about the product itself but mentions the company’s current market research drive to work out how to sell it.

“We’re not promising a cure…….What we hope to do is provide families with an accurate picture of their risk.”

The company itself, SureGene, has a rather dowdy web-site which mentions patented LocusLock(TM) technology which appears to be a linkage method which outputs locus interaction information not normally generated by such studies.
Upon further investigation, I find once more that I am several months behind the rest of the World and that the implications of this test have already been discussed and commented on by others: include some very courteous and moderate responses from a SureGene manager. The company appears to have published one schizophrenia gene candidate, SULT4A1, which seems to have been found through other means but its significance is unclear at present.

Three questions spring to mind:-

  1. What is the nature of the ‘kit’ itself. I suspect it is a tube for the colection of saliva which is then shipped back to the company for DNA typing. I can’t imagine what protein target or bodily fluid might currently be suitable for an alternative ‘dip-stick’ type of schizophrenia diagnostic kit (e.g. hCG and urine for pregnancy tests).
  2. Because schizophrenia is genetically complex, shows incomplete penetrance, and differs in cause between unrelated individuals, what might a DNA test be looking for? They seem to imply that their LocusLock(TM) technology has identified a network of interacting candidates….a better approach than looking at a single gene but still hit-or-miss. For instance, they may know the contributory genes in an ideal world, but do they know (and have assays for) the underlying mutations?
  3. What are the ethical and personal issues surrounding such a test? Would the test result be presented as a definitive finding or reveal its status as a calculated assessment of % risk? What life-changing decisions would be based on a test result? How many Canadian ‘online meds’ sites would spring up, a la Tamiflu, to supply a booming market for preventative anti-psychotic drug regimes? BuUyyy C#e@p 0l@nz@p1ne spam, anyone?

Time and the market-place will determine this and other attempts at diagnostics. Personally, I think the science isn’t there yet….but I think this should serve as a wake-up call for the genetic counsellors, at least.

Comments

Are mental illnesses caused by QTLs?

A Quantitative Trait (QT) is a phenotype/feature/measurement of an organism that can fall anywhere on a continuous range. So height, intelligence, metabolic rate, longevity etc. all sit within this class of traits. On the other hand, there are traits such as eye colour, blood group, tongue rolling etc. which are qualitative and discrete in nature. As common sense might dictate, the distinction between these two sets of traits is mirrored in the complexity of the genetics behind them. Many genes are predicted to simultaneously contribute to quantitative traits and these genes are termed QT Loci (QTLs: loci referring to the locations of these genes on the chromosomes). A handful of genes at most are thought necessary to control a qualitative trait.
A very recent paper from Jonathan Flint’s laboratory (Oxford, UK) describes a large mouse genetics study that aimed to uncover the genetic contributions to a number of measurable traits (including behavioural, metabolic, weight, biochemical, blood properties etc.).

The considerable advance described in this paper was the scale of the project coupled with the use of what they call heterogeneous stock mice. Basically these are derived from the interbreeding of a different original mouse strains (each with their own particular trait characteristics) so that, after many generations, mice are produced with an apparently random mix of these traits caused by the shuffling and mixing of the original genetic material on their chromosomes. By using markers which can tell which parts of which chromosomes came from which original mouse strain it was possible, with necessarily powerful and complicated statisitical methods (I don’t understand them so won’t attempt to summarise them!), to work out the approximate location and contribution of many QTLs for a given trait. The exact identity of the QTLs will doubtless follow in subsequent publications.
The upshot of this gargantuan effort is that, for the average trait, many QTLs are responsible, but each one is unlikely to contribute to much more than 5% of the trait and that only 75% of the genetic effect on the trait could be pinned down to detectable QTLs (i.e. many other undetectable QTLs exist, each contributing very small amounts to the final trait measurement).

What are the implications of this work? The authors have achieved the first steps in making the identification of QTLs a realistic possibility. However, the link to human disease is a little harder to make.

Of course, I have a vested interest in hoping that the QTL story is not relevant to the identification of genes involved in mental illness because it would make it a much harder task. And in that respect, there are also a few conceptual issues I have with equating QTLs with diasease genes.

Firstly, these mice are all well. A few years back I heard a suggestion that the genes for intelligence could be cloned by identifying the genes responsible for mental retardation (UK: learning disability). Yes, both intelligence and mental retardation can be defined in terms of IQ but the comparison prety much ends there. An analogy illustrates the problem: if the speed of a car represents IQ then it is possible to list the modifications/properties (QTLs) which might alter the performance - engine capacity, tyre type, turbo-charging, air intakes, computer tuning etc. etc. However, contrast this with the things that can go wrong - fan belt broken, accelerator pedal snapped, puncture, oil leak etc. etc. - and bear in mind that these factors play only minor roles in determining the car’s ‘performance’ per se. Despite this being only an analogy, we should not be surprised if natural variations in the ’state of wellness’ have little bearing on common illness.
Secondly, the genes responsible for mental illness (or any other complex genetic disorder, for that matter) exist as a consequence of spontaneous mutations in genes which have then been distributed and selected among populations which have then been scattered by numerous ancient migrations. All these factors have determined the current set of mental illness gene variants present at reasonable frequencies in our human populations. This is also true for the specific QTLs present in the parental strains of mice used in these experiments. Whether there is likely to be susbtantial overlap in contributory genes for any trait/disease between mouse and man should be a subject for debate rather than an assumption.

In summary, is mental illnes (in an individual rather than a population) caused by small-effect changes in many genes acting in concert or by the actions of one or few genes with stronger effects? I believe the current state of play, as evidenced by the emerging genes, suggests the latter is more likely. Indeed, the current techniques such as linkage and case-control association studies employed in the search for these genes have a definite lower limit in their sensitivity which means that we have to hope that this is the case. I guess the fact that those are the kinds of genes we are seeing published recently may just be a result of the use of these techniques - ascertainment bias as it is known - but there is nothing to suggests that we are looking solely at a QTL effect.
Next post I will discuss another recent paper which describes further work linking a variant of a gene and its link with bipolar disorder and major depression: a potentially important major candidate for these disorders.

Comments

Going over old ground

A little learning is a dangerous thing; drink deep, or taste not the Pierian spring: there shallow draughts intoxicate the brain, and drinking largely sobers us again.

Alexander Pope - An Essay on Criticism, 1709

It is often the young fields like psychiatric genetics which suffer from over-interpretation in the face of minimal facts. I previously worked in the field of DNA methylation and the often-whispered joke was that there were more published reviews on the subject than primary research papers. Psychiatric Genetics is definitely showing a similar trend too.

I have no probems with this state of affairs in the most part. Everyone needs a digestable point of entry into a new field and a covenient method to delve deeper into particular aspects. However, there is an emerging trend in certain papers (reviews and others) to construct biological models of schizophrenia, bipolar disorder or other complex disorder biology based upon aggregated data. Inevitably, these models are used to add weight to candidate gene findings or to suggest novel candidates.

Over-cooking the Bacon

You may be familar with the thought game ‘six degrees of Kevin Bacon‘ or its intellectual predecessors. Basically, the theory behind this can be summarised as ‘because things are connected (in many different ways) to many other things, it doesn’t take many steps to connect any one thing to any other thing’. ‘Things’, in this context, can refer to citizens of the World, film actors or - perhaps -genes in the genome.

In the case of genes, the ways they can be connected with other genes is manifold:

  1. they look the same (sequence homology)
  2. they participate in a similar process
  3. they are found in the same tissue or sub-cellular region
  4. they are regulated by the same stimuli
  5. they are expressed at a similar developmental time-point
  6. they directly interact (protein binding, enzyme/substrate interaction)

A number of bioinformatics approaches have attempted to construct networks of these interactions. These have been based on trawling through the databases of published scientific papers in order to extract ‘co-incidences’ or on the grouping together of genes according to keyword definitions (gene ontologies) assigned to each gene. These bioinformatic strategies have principally been used to suggest genes involved in a given disease/process and to provide meaningful interpretation to data-spawning experiments such as expression microarrays (a test which looks at how a state or stimulus alters the use of a large set of genes).

So there have been publications with titles like ‘Post-mortem studies on schizophrenic brain gene expression imply changes in genes involved in X, Y and Z processes’ or ‘Bioinformatic approaches demonstrate that schizophrenia is a disorder of p and q pathways’. And this is where I have conceptual difficulties in these approaches - not necessarily with the veracity of the results - but in trying to understand how they can contribute to the future development of the psychiatric genetics.

Green screen - recycling old knowledge

Two problems spring to mind with this methodology. Firstly, the ’six degrees of molecular interaction’ issue introduced above suggests that ‘over-linking’ of genes into apparently signficant pathways is probable. This ‘noise’ would cloud the specific ’signal’ relevant to the study’s aim. Secondly, there is no additional information generated in the bioinformatic cataloguing beyond the original published data - and no easy means to ensure that the source data is of uniform quality and format. Therefore, although some quantitative evidence will result from the interrogation of the data, no new qualitative findings can result - you basically get out what you put in and nothing more. If gene S (causing schizophrenia) isn’t on your microarray chip, wasn’t in your yeast two-hybrid expression library or doesn’t interact with your chosen bait, is expressed at low levels in the brain, shares no homology with other genes or, heaven forbid, doesn’t fit into previously hypothesised biological pathways implicated in schizophrenia….then you are not going to find it, however much you shake up the input data.
If any readers have examples where this approach has yielded unexpected, novel findings which have been confirmed by specific experimental research then I would be keen to hear about it…and eat my words!

Having said all that…

Having said all that, if I had the opportunity and means to carry out this kind of work or to use its consequences to justify my own findings, then I would do so in a shot. Clutching at impressive straws is the psychiatric genetics way.

Comments